Home  /  Resource Library  /  The MAGNOLIA Trial: Zanubrutinib, a Next Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

The MAGNOLIA Trial: Zanubrutinib, a Next Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

Results of a study examining zanubrutinib for treatment of relapsed marginal zone lymphomas.